肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
3期
221-225
,共5页
叶旭%刘雯%韩亚骞%陈艳平%吴湘玮%姜翠红%肖帅
葉旭%劉雯%韓亞鶱%陳豔平%吳湘瑋%薑翠紅%肖帥
협욱%류문%한아건%진염평%오상위%강취홍%초수
鼻咽癌%奈达铂%顺铂%同步放疗
鼻嚥癌%奈達鉑%順鉑%同步放療
비인암%내체박%순박%동보방료
Nasopharyngeal carcinoma%Nedaplatin%Cisplatinumcis%Concurrent Radiotherapy
目的:探讨奈达铂和顺铂同步放疗治疗鼻咽癌的近期疗效及毒副作用。方法选取2008年1月~2013年1月在我院首次行放射治疗的102例局部晚期鼻咽癌患者,随机分为顺铂同步化疗组(A组,n=50)与奈达铂同步化疗组(B组,n=52)。A组给予顺铂同步化疗,B组给予奈达铂同步化疗,比较两组患者的近期疗效(原发灶及颈部淋巴结退缩情况)及毒副反应的发生情况。结果同步放化疗后,两组的原发灶及颈部淋巴结退缩总有效率比较,差异均无统计学意义(P>0.05);B组患者呕吐及口腔黏膜反应的发生率均较A组明显降低,差异具有统计学意义(P<0.05)。结论奈达铂与顺铂同步放疗治疗鼻咽癌的临床疗效相当,但奈达铂的安全性更高。
目的:探討奈達鉑和順鉑同步放療治療鼻嚥癌的近期療效及毒副作用。方法選取2008年1月~2013年1月在我院首次行放射治療的102例跼部晚期鼻嚥癌患者,隨機分為順鉑同步化療組(A組,n=50)與奈達鉑同步化療組(B組,n=52)。A組給予順鉑同步化療,B組給予奈達鉑同步化療,比較兩組患者的近期療效(原髮竈及頸部淋巴結退縮情況)及毒副反應的髮生情況。結果同步放化療後,兩組的原髮竈及頸部淋巴結退縮總有效率比較,差異均無統計學意義(P>0.05);B組患者嘔吐及口腔黏膜反應的髮生率均較A組明顯降低,差異具有統計學意義(P<0.05)。結論奈達鉑與順鉑同步放療治療鼻嚥癌的臨床療效相噹,但奈達鉑的安全性更高。
목적:탐토내체박화순박동보방료치료비인암적근기료효급독부작용。방법선취2008년1월~2013년1월재아원수차행방사치료적102례국부만기비인암환자,수궤분위순박동보화료조(A조,n=50)여내체박동보화료조(B조,n=52)。A조급여순박동보화료,B조급여내체박동보화료,비교량조환자적근기료효(원발조급경부림파결퇴축정황)급독부반응적발생정황。결과동보방화료후,량조적원발조급경부림파결퇴축총유효솔비교,차이균무통계학의의(P>0.05);B조환자구토급구강점막반응적발생솔균교A조명현강저,차이구유통계학의의(P<0.05)。결론내체박여순박동보방료치료비인암적림상료효상당,단내체박적안전성경고。
Objective To investigate the short-term efficacy and adverse effects of nedaplatin or cisplatinumcis plus concurrent radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods A total of 102 patients with local advanced nasopharyngeal carcinoma admitted in our hospital for the first radiotherapy between January 2008 and January 2013 were selected and randomly divided into two groups. Group A (n=50) was given venous 80 mg·m-2 cisplatinumcis every 22~28 days, and group B (n=52) received Nedaplatin by 80 mg·m-2 via intravenous infusion every 22~28 days, all in the conventional radiotherapy duration. The regression of primary lesion and cervical lymph node and incidence of adverse re-actions after treatment were compared between the two groups. Results After concurrent chemoradiotherapy, no significant difference was found in the efficacy of regression of primary lesion and cervical lymph node (P>0.05). The incidence rates of vomiting and oral mucosa reaction of group B were significantly lower than those of group A(P>0.05). Conclusion The ef-ficacy of nedaplatin plus concurrent radiotherapy in the treatment of advanced nasopharyngeal carcinoma was equal to that of cisplatinumcis plus concurrent radiotherapy, but nedaplatin was much safer.